Mastic Gum for Health & Longevity

Evidence Review created on 04/27/2026 using AI4L / Opus 4.7

Also known as: Chios Mastic, Mastiha, Mastic, Chios Mastiha, Pistacia lentiscus var. chia Resin

Motivation

Mastic gum is an aromatic resin obtained by tapping the trunk and branches of Pistacia lentiscus var. chia, an evergreen shrub cultivated almost exclusively in 24 medieval villages on the southern part of the Greek island of Chios. The hardened “tears” of resin contain triterpenic acids, polyphenols, and a volatile essential oil rich in monoterpenes that give mastic its characteristic aroma and bioactivity. Modern interest centers on its anti-inflammatory, antimicrobial, and lipid-lowering properties.

Mastic has been used as a traditional medicine across the eastern Mediterranean for over 2,500 years for digestive complaints and oral hygiene. The European Medicines Agency formally recognized it in 2015 as a traditional herbal medicinal product for mild dyspeptic disorders and minor skin inflammation, and a small but expanding body of human trials now supports applications in functional dyspepsia, dyslipidemia, and inflammatory bowel disease.

This review examines the clinical evidence for mastic gum, including its demonstrated benefits, known risks, interactions, sourcing considerations, and practical protocols, to inform decision-making in the context of long-term health optimization.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Mastic (plant resin)

A Grok-fact-checked Grokipedia entry covering mastic’s botanical origin from Pistacia lentiscus var. chia, its Protected Designation of Origin status from the European Union, traditional harvest methods recognized by UNESCO, the resin’s triterpene-dominated composition (~65–70% triterpenes), and its modern medicinal positioning.

Examine

No dedicated Examine.com article for mastic gum was found. Examine.com primarily covers more widely studied supplements and does not appear to maintain a standalone reference page for this intervention.

ConsumerLab

No dedicated ConsumerLab review of mastic gum was found. ConsumerLab references mastic only peripherally within its oral-health and gum-disease supplement category pages and has not published an independent product test of mastic gum capsules or chewing resin.

Systematic Reviews

A summary of the systematic reviews and high-quality evidence syntheses evaluating mastic gum across its main therapeutic indications.

Non-Chinese herbal medicines for functional dyspepsia - Báez et al., 2023

A 2023 Cochrane systematic review of herbal therapies for functional dyspepsia covering multiple botanicals including mastic gum; it judged evidence quality as low to very low across most agents but identified mastic as one of the candidates with positive randomized data warranting further trials.
The Effect of Mastic Chios Supplementation in Inflammatory Bowel Disease: A Systematic Literature Review - Mavroudi et al., 2023

A PRISMA-compliant (Preferred Reporting Items for Systematic Reviews and Meta-Analyses, a standard reporting framework) systematic review of eight clinical and preclinical studies (mostly randomized controlled trials at 2.2–2.8 g/day for 4 weeks to 6 months) concluding that mastic Chios shows significant antioxidant and anti-inflammatory effects in inflammatory bowel disease but calling for larger high-quality trials before clinical recommendations.
Effects of Pistacia genus on gastrointestinal tract disorders: A systematic and comprehensive review - Adibifard et al., 2024

A systematic review of 48 clinical and animal studies of Pistacia species in gastrointestinal disease — including 6 clinical and 13 animal Pistacia lentiscus studies in inflammatory bowel disease and 7 clinical studies in functional gastrointestinal disorders — finding that terpenoid components drive most effects through anti-inflammatory and anti-oxidative mechanisms.

Mechanism of Action

Mastic gum exerts its biological effects through a complex mixture of more than 120 identified compounds. The dominant pharmacologically active classes are:

Triterpenic acids and alcohols (~65–70% of resin weight): including masticadienonic acid, isomasticadienonic acid, oleanonic acid, and tirucallol. These oleanane- and lupane-type pentacyclic triterpenes account for most of the antimicrobial, anti-ulcer, and lipid-modifying activity. Acidic triterpenes inhibit bacterial growth (notably Helicobacter pylori) by disrupting membrane integrity, while neutral triterpenes contribute to NF-κB (nuclear factor kappa B, a master inflammation-control transcription factor) suppression.
Volatile essential oil (~2–3% of resin): a monoterpene fraction dominated by α-pinene, β-myrcene, and β-pinene. The essential oil mediates several of the cardiovascular and antibacterial actions and is now being studied as a separate therapeutic preparation under the name Chios Mastiha Essential Oil (CMO).
Polyphenols and a natural polymer (cis-1,4-poly-β-myrcene): the polymer is the chewy matrix and is largely indigestible; polyphenols contribute additional antioxidant capacity.

The principal proposed mechanisms of clinical relevance are:

Anti-inflammatory action through inhibition of NF-κB signaling and downregulation of microRNA-155 (a small regulatory RNA that promotes Th17 immune responses), which lowers IL-6, TNF-α, and other pro-inflammatory cytokines.
Antimicrobial activity against gram-positive and gram-negative bacteria, including H. pylori, Streptococcus mutans, and several periodontal pathogens; activity is largely a membrane-disruption effect of triterpene acids.
Lipid and glucose modulation — mastic appears to inhibit hepatic cholesterol synthesis and improve insulin sensitivity, with prebiotic effects on the gut microbiota (increased microbial diversity, downregulation of pro-inflammatory taxa such as Flavonifractor) likely mediating part of these systemic effects.
Mucoprotective and anti-ulcer effects — triterpenes appear to enhance gastric mucus production and reduce oxidative damage to the gastric epithelium.

Mastic gum is not a single pharmacological compound, so half-life, selectivity, and metabolism are not characterized in the manner of a defined drug; the active triterpenes undergo hepatic metabolism but no specific cytochrome P450 (CYP, drug-metabolizing enzymes) interactions have been formally established. Where competing mechanistic explanations exist — for example, whether the cholesterol-lowering effect is direct (HMG-CoA reductase-like inhibition by triterpenes; HMG-CoA reductase is the rate-limiting enzyme in cholesterol biosynthesis and the target of statin drugs) or indirect (microbiota- and bile-acid-mediated) — both pathways have experimental support and are likely to operate together.

Historical Context & Evolution

Mastic has one of the oldest continuous medicinal histories of any botanical. References to its use for digestive complaints, breath freshening, and wound healing appear in Hippocrates, Theophrastus, Dioscorides, and Galen, and Byzantine pharmacopoeias preserved its place in eastern Mediterranean medicine throughout the Middle Ages. Cultivation became economically important under Genoese and then Ottoman administration of Chios, and the resin was a strategic commodity protected by harsh penalties for theft. UNESCO recognized the mastic-cultivation tradition as Intangible Cultural Heritage of Humanity in 2014.

Modern scientific reassessment began in the 1980s with Greek and Japanese phytochemical work characterizing the triterpene fraction, but the inflection point came in 1998 when a brief letter to The New England Journal of Medicine by Huwez and colleagues showed in vitro killing of Helicobacter pylori. This single paper, despite being a non-peer-reviewed correspondence, drove a wave of subsequent clinical trials. Some of those trials were disappointing — for example, the 2010 Dabos H. pylori eradication study found only modest activity at 350 mg three times daily, with full eradication in roughly one third of treated patients and no advantage when combined with a proton-pump inhibitor. Other trials in functional dyspepsia and dyslipidemia were more uniformly positive.

The European Medicines Agency formally classified mastic gum as a traditional herbal medicinal product in 2015 with two indications: mild dyspeptic disorders and minor skin inflammation/wound healing. This European approval reflects a “traditional use” pathway based on documented historical use rather than a full pharmaceutical dossier, and that distinction is sometimes mischaracterized in marketing claims. Earlier pessimism about the H. pylori application has not been “debunked” so much as refined: monotherapy effects are real but modest, and the more recent direction of research is mastic as an adjunct to standard antibiotic regimens, where small randomized trials suggest improved tolerability and possible eradication-rate benefits.

Expected Benefits

Medium 🟩 🟩

Functional Dyspepsia Symptom Relief

Multiple randomized controlled trials, including a 148-patient placebo-controlled study by Dabos et al. (350 mg three times daily for three weeks) and a 2025 three-way crossover trial by Kleftaki et al. comparing mastic capsules and mastic-water against no intervention, have shown clinically meaningful reductions in upper-abdominal pain, epigastric burning, bloating, and heartburn in patients meeting Rome II/IV criteria for functional dyspepsia. The European Medicines Agency’s 2015 designation of mastic as a traditional herbal medicinal product for mild dyspeptic disorders is grounded in this trial base. Effects appear within days to weeks and are not accompanied by the dependence or rebound seen with proton-pump inhibitors.

Magnitude: Approximately 77% of treated patients reported meaningful symptom improvement vs. ~40% on placebo at 3 weeks (Dabos 2010); symptom-score reductions of 25–35% are typical across trials.

Total Cholesterol and LDL Reduction

The CHIOS-MASTIHA randomized controlled trial (156 healthy volunteers with elevated cholesterol, 1 g/day crude mastic for 8 weeks) showed total cholesterol reductions of ~11.5 mg/dL and fasting glucose reductions of ~4.5 mg/dL, with stronger effects in overweight and obese participants. The follow-up MASTIHA-OIL trial (160 volunteers, 200 mg of Chios Mastiha essential oil daily for 8 weeks) reported total cholesterol reductions of ~9% and LDL (low-density lipoprotein, the cholesterol-carrying particle most strongly associated with cardiovascular risk) reductions of ~12% versus placebo, with significant additional drops in triglycerides and a small HDL (high-density lipoprotein) increase. Effects are modest in absolute terms but consistent across trials, well tolerated, and biologically plausible given preclinical hepatic cholesterol-synthesis data.

Magnitude: ~5–12% reduction in total and LDL cholesterol over 8 weeks; ~4–5 mg/dL reduction in fasting glucose.

Inflammatory Bowel Disease Activity

Several small randomized controlled trials in active and quiescent inflammatory bowel disease (IBD, an umbrella term for chronic immune-mediated bowel inflammation including ulcerative colitis and Crohn’s disease) at 2.2–2.8 g/day for 1–6 months have shown improved disease activity scores, increased Inflammatory Bowel Disease Questionnaire (IBDQ) quality-of-life scores, and beneficial shifts in fecal inflammatory markers (lysozyme, fibrinogen). The 2023 Mavroudi systematic review concluded that mastic Chios appears to have a positive effect on regulation and management of IBD as adjunctive therapy, while emphasizing that all trials to date are small and that mastic should be viewed as adjunctive to, not replacement of, standard medical therapy.

Magnitude: Clinically meaningful IBDQ improvements (>16 points) and ~30–40% reductions in selected fecal inflammatory markers in trial participants.

Low 🟩

Anti-Helicobacter pylori Activity

Initial in vitro work (Huwez 1998) showed potent killing of seven H. pylori strains at low concentrations, but human eradication trials have been more modest. The 2010 Dabos pilot RCT (randomized controlled trial) achieved eradication in ~30–38% of patients on mastic monotherapy at 350–1,050 mg three times daily for two weeks, well below the ~77% achieved in the standard antibiotic comparison arm. A more recent 2026 Tulsian pilot trial added mastic to bismuth quadruple therapy and reported improved tolerability and a non-significant trend toward higher eradication rates. The biological signal is genuine but the magnitude as monotherapy is insufficient to replace antibiotic regimens; current best evidence supports mastic as a possible adjunct, not a primary eradication agent.

Magnitude: ~30–38% eradication rate as monotherapy vs. ~77% for standard triple therapy; possible additive benefit when combined with antibiotic protocols.

Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement ⚠️ Conflicted

The MAST4HEALTH multicenter randomized controlled trial (98 NAFLD patients across Greece, Italy, and Serbia, 6 months of supplementation) was the first major trial in this indication. Mastiha was not superior to placebo for the primary endpoints (iron-corrected T1 (cT1) and Liver Inflammation Fibrosis (LIF) score) in the overall population, but did show significant improvements in severely obese patients (body mass index, BMI, >35 kg/m²) and beneficial shifts in gut microbiota and lipid metabolites in the full cohort. Animal studies in advanced non-alcoholic steatohepatitis models show clearer reductions in alanine aminotransferase, hepatic steatosis, and collagen content. The conflict between the negative primary endpoint and the positive subgroup and secondary findings is the basis for the conflicted flag.

Magnitude: No effect on liver imaging in unselected NAFLD; significant improvement in cT1/LIF in BMI >35 subgroup; consistent microbiota and metabolite shifts.

Oral Plaque and Gingival Health

Small randomized trials of mastic-based chewing gum and toothpaste (most recently the 2025 Alexiou orthodontic-patient trial) have shown reductions in dental plaque accumulation, plaque indices, gingival indices, and breath volatile sulfur compounds compared with control gum or toothpaste. The 2023 Alwadi state-of-the-art review concluded that mastic-containing oral products inhibit plaque accumulation and have activity against several cariogenic and periodontal pathogens, but most trials are small and short. The benefit appears real but is comparable in magnitude to other established oral hygiene measures rather than transformative.

Magnitude: ~15–30% reductions in plaque indices in trial participants; modest reductions in breath volatile sulfur compounds.

Cardiometabolic Risk in Metabolic Syndrome

The 2023 Gioxari Chios Mastiha Essential Oil trial in 94 metabolically unhealthy adults (200 mg/day for 3 months as adjunct to existing treatment) reported significant reductions in systolic blood pressure, triglycerides, LDL cholesterol, alanine aminotransferase, body weight, percent body fat, visceral fat, and oxidized LDL, plus an increase in adiponectin, with no adverse effects. This is a single trial of an essential-oil preparation rather than crude resin and has not been independently replicated; the consistent direction of multiple secondary endpoints, however, suggests a coherent metabolic effect that warrants larger confirmatory studies.

Magnitude: Triglyceride reduction ~15%, body weight loss of 1–2 kg, modest systolic blood pressure reduction; single trial.

Speculative 🟨

Anticancer Activity

Multiple in vitro studies show that mastic triterpenes (notably isomasticadienonic acid) induce apoptosis (programmed cell death) in colon, prostate, lung, and pancreatic cancer cell lines, and animal xenograft studies suggest tumor-growth inhibition. The mechanistic basis is plausible (mitogen-activated protein kinase modulation, NF-κB suppression), but no human clinical trials of mastic for cancer prevention or treatment exist. Any anticancer claim in marketing material is at present mechanistic and animal-based only.

Bone Loss Protection

A 2021 ovariectomized-rat study by Pepe et al. reported preservation of trabecular bone mineral density with chronic mastic supplementation, suggesting a possible role in postmenopausal bone loss. No human trials exist; the basis is a single preclinical model.

Cognitive and Stress Benefits via Chewing

Beyond the resin’s biochemistry, the act of chewing a hard resin like mastic engages masseter and temporalis musculature and stimulates cerebral blood flow and the hypothalamic-pituitary-axis stress response in ways that some preclinical work has linked to mood and cognitive performance. This is mechanistic only; no controlled human trial has shown cognitive or mood benefit from chewing mastic specifically.

Benefit-Modifying Factors

Body mass index: The strongest signals in the cardiometabolic and NAFLD trials were observed in overweight, obese, or severely obese subgroups (BMI >25 in CHIOS-MASTIHA, BMI >35 in MAST4HEALTH). Lean individuals appear to derive less measurable benefit from supplementation.
Baseline cholesterol and glucose: Hypolipidemic effects are most apparent in those with elevated baseline total cholesterol (>200 mg/dL); near-optimal baseline values leave less room for measurable improvement.
Sex-based considerations: No sex-stratified efficacy data are available from the major mastic trials, and most trials enrolled mixed populations without sex-by-treatment subgroup analysis. Differences in hepatic lipid metabolism and gut microbiota composition between sexes are biologically plausible modifiers but have not been characterized for mastic specifically.
Pre-existing inflammatory bowel disease activity: In active IBD, benefit appears largest in patients on stable conventional therapy; mastic is best evidenced as adjunctive rather than monotherapy.
Age and metabolic context: Older adults with established dyslipidemia or metabolic syndrome may derive greater absolute benefit than younger, metabolically healthy adults, although age-stratified trial data are limited. Individual genetic polymorphisms affecting lipid metabolism (e.g., APOE genotype, the gene encoding apolipoprotein E that influences lipid transport, where APOE4 carriers tend to have higher LDL responses to dietary interventions) may plausibly modify cholesterol-lowering responses, but no pharmacogenetic data on mastic exist.
Microbiome state: Preliminary metabolomic and microbiota work from the MAST4HEALTH program suggests that response is associated with baseline gut microbial composition, with greater shifts and apparent benefit in those with more dysbiotic baseline profiles. This is hypothesis-generating only.

Potential Risks & Side Effects

Low 🟥

Gastrointestinal Discomfort

Mild headache, nausea, upset stomach, dyspepsia, constipation, or diarrhea are the most commonly reported side effects in clinical trials and observational reports, generally at low frequency and resolving with dose reduction or discontinuation. The CHIOS-MASTIHA, MASTIHA-OIL, MAST4HEALTH, and Mastic Chios IBD trials all reported no liver, renal, or serious gastrointestinal adverse events at 1–2.8 g/day for up to 6 months, suggesting that typical dosing is well tolerated.

Magnitude: Reported in roughly 5–10% of users in clinical trials; generally mild and transient.

Allergic Contact Dermatitis and Cross-Reactivity

Mastic belongs to the Anacardiaceae family (which includes pistachio, cashew, mango, and poison ivy), and contact dermatitis from topical mastic — particularly from mastic-containing surgical adhesives such as Mastisol — is well-documented. A case series found that 13 of 18 Mastisol-allergic patients (72%) had positive patch tests to gum mastic, and cross-reactivity with linalool-containing essential oils has been reported. Oral allergic reactions appear less common but cannot be excluded in individuals with known Anacardiaceae sensitivities; the absence of a botanical relationship to actual Pistacia vera (pistachio nut) means tree-nut allergy alone is not necessarily predictive of mastic allergy.

Magnitude: Topical: high among Mastisol-allergic individuals; oral: rare, not quantified across general populations.

Tooth and Jaw Strain from Heavy Chewing

When mastic is used as a chewing resin (rather than encapsulated), the resin is harder than conventional chewing gum and can cause jaw fatigue, temporomandibular joint discomfort, or accelerated wear of dental work with prolonged or aggressive use. Dental and orofacial-pain experts cited on the Huberman Lab podcast caution that “we are only meant to chew for sustenance” and that overuse of hard chewing tools, including mastic, can hurt the jaw.

Magnitude: Not formally quantified; reports are clinical and anecdotal, more common with daily prolonged chewing sessions.

Mercury Liberation from Amalgam Fillings

The intensity of chewing required for mastic resin can mechanically wear and fracture older dental amalgam fillings, potentially liberating elemental mercury that may then be partially absorbed through inhalation or swallowing. This mechanism is biologically plausible (chewing on hard surfaces is known to increase mercury release from amalgams) and has been explicitly raised by Andrew Huberman as a precaution. Quantitative data on mercury exposure specifically from mastic chewing are not available.

Magnitude: Not quantified in available studies.

Gastrointestinal Bezoar (with Excessive Chewing-Resin Intake)

Mastic resin contains a non-digestible polymer fraction (cis-1,4-poly-β-myrcene). In rare reports, accidental ingestion of large amounts of chewing gum in general has been associated with the formation of bezoars (compacted indigestible matter that can obstruct the bowel), particularly in children. No published mastic-specific bezoar case reports exist, but the mechanism is shared with other chewing gums.

Magnitude: Rare; not quantified specifically for mastic; mostly reported in children with excessive chewing-gum ingestion.

Speculative 🟨

Drug-Metabolism Interactions

In vitro work suggests mastic triterpenes may modulate certain CYP enzymes, but no clinical pharmacokinetic studies of mastic with prescription drugs have been conducted. Concern is mechanistic only; no documented clinical interactions exist.

Pregnancy and Lactation Safety

There are no controlled human safety data on mastic gum supplementation in pregnancy or lactation. Traditional culinary use of mastic as a flavoring is presumed safe at small amounts, but supplemental gram-level doses in pregnancy are not recommended given the absence of data — this is a precautionary stance, not a documented harm signal.

Risk-Modifying Factors

Anacardiaceae allergy history: Individuals with documented contact allergy to mastic-containing adhesives (e.g., Mastisol), mango sap, poison ivy, or related plants have a substantially higher probability of cross-reactive contact dermatitis and should approach mastic with caution. Botanical pistachio (Pistacia vera) nut allergy is not a strict predictor but warrants additional caution.
Existing dental amalgam fillings: Adults with multiple older silver-mercury fillings should consider encapsulated mastic rather than the chewing resin to avoid mechanical wear and possible mercury liberation.
Pre-existing temporomandibular joint dysfunction: Anyone with bruxism, jaw pain, or temporomandibular joint disorder is more likely to develop or exacerbate jaw discomfort with prolonged mastic chewing.
Sex-based considerations: No sex-specific risk patterns have been identified in the trial literature.
Age-related considerations: Older adults with reduced dental integrity, dentures, or complex restorative work are at higher risk of dental damage from chewing the resin form; encapsulated mastic is a better option in this group.
Active inflammatory bowel disease flare: While trials in active IBD have shown no harm, very rarely a botanical adjunct can be subjectively poorly tolerated during a severe flare; introduction is best delayed until inflammation is at least partially controlled.
Genetic polymorphisms: No specific genetic polymorphisms have been identified that meaningfully modify mastic-related risk or side-effect profile. This may reflect the absence of pharmacogenetic study rather than confirmed lack of effect; until characterized, no genotype-based risk stratification can be recommended.
Baseline biomarker levels: No baseline biomarker has been shown to predict adverse-event likelihood with mastic. Standard clinical assessment of liver enzymes, renal function, and complete blood count before high-dose or prolonged use is reasonable for general supplement-safety hygiene rather than a mastic-specific signal.

Key Interactions & Contraindications

Anti-hypertensives (e.g., angiotensin-converting-enzyme inhibitors such as lisinopril, angiotensin-receptor blockers such as losartan, calcium-channel blockers such as amlodipine): mastic essential oil has shown blood-pressure-lowering activity in metabolic-syndrome trials; severity is caution, with the clinical consequence being possible additive systolic blood pressure reduction. Mitigation: monitor home blood pressure when adding mastic to an existing antihypertensive regimen.
Lipid-lowering agents (e.g., statins such as atorvastatin, ezetimibe, bile-acid sequestrants): mastic has demonstrated independent total-cholesterol and LDL-lowering effects; severity is caution with the clinical consequence of additive lipid lowering. Mitigation: this is generally desirable, but recheck lipid panel 8–12 weeks after addition and adjust statin dose if indicated.
Anti-diabetic drugs (e.g., metformin, sulfonylureas such as glimepiride, sodium-glucose cotransporter-2 inhibitors such as empagliflozin): mastic has small fasting-glucose-lowering effects; severity is caution with possible additive hypoglycemia risk in those on insulin or sulfonylureas. Mitigation: monitor capillary blood glucose more frequently in the first 4 weeks.
Proton-pump inhibitors (PPIs) (e.g., omeprazole, pantoprazole): the 2010 Dabos H. pylori trial unexpectedly found that combining mastic with pantoprazole eliminated the eradication signal seen with mastic alone, suggesting a possible negative pharmacodynamic interaction in the H. pylori application; severity is monitor, with the clinical consequence of reduced anti-H. pylori effect. Mitigation: if mastic is used for H. pylori, separate from PPI by several hours or use alone.
Antibiotics in H. pylori eradication regimens (e.g., amoxicillin, clarithromycin, metronidazole, bismuth subcitrate): early data from the 2026 Tulsian trial suggest mastic added to standard bismuth quadruple therapy improves tolerability and may modestly increase eradication rates; severity is monitor; mitigation is none required, but this is properly an adjunct rather than a replacement for full eradication therapy.
Other supplements with overlapping effects: zinc-carnosine, bismuth subcitrate, deglycyrrhizinated licorice (DGL), and slippery elm all have overlapping gastric mucosal protection or antimicrobial actions; combining them is generally well tolerated but their additive benefits are not formally quantified. Berberine, also used for H. pylori and dyslipidemia, has overlapping cholesterol-lowering effects and may produce additive lipid reductions (caution with lipid monitoring).
Surgical contexts: mastic-containing surgical adhesives such as Mastisol can sensitize patients to oral mastic; severity is caution and mitigation is to avoid further mastic exposure if a Mastisol reaction has occurred.
Populations to avoid: pregnancy at any trimester and lactation (no controlled human data, precautionary avoidance of supplemental gram-level doses); documented contact allergy to mastic, Mastisol adhesive, or other Anacardiaceae (positive patch test to gum mastic, history of Mastisol-induced dermatitis); severe active inflammatory bowel disease flare (Mayo score ≥10 for ulcerative colitis or Crohn’s Disease Activity Index ≥450) in the absence of gastroenterology-led supervision; children under 12 years of age outside trial settings.

Risk Mitigation Strategies

Start at a low dose with gradual titration: Begin with 250–500 mg per day for the first 5–7 days before advancing to a typical 1–2 g/day target dose, to detect early gastrointestinal intolerance and allergic reactions before high-dose exposure.
Choose encapsulated resin over chewing form when dental wear is a concern: Adults with amalgam fillings, complex restorative work, dentures, bruxism, or temporomandibular joint disorder should default to capsule formulations to avoid mechanical mercury liberation and dental fatigue.
Limit chewing-resin sessions to short durations: When mastic is used as chewing resin, sessions of 10–15 minutes once or twice daily are sufficient for any documented oral or jaw effect; prolonged hour-long chewing is unnecessary and increases risk of jaw fatigue and dental damage.
Patch-test before topical use: Apply a small amount of any mastic-containing topical preparation to a forearm for 24 hours before broader application, particularly in those with a history of contact dermatitis or Anacardiaceae allergy.
Avoid in known Mastisol-allergic individuals: A documented Mastisol reaction predicts a high probability of mastic cross-reactivity (~72% in published case series); these individuals should avoid both topical and oral mastic until allergy testing clarifies risk.
Re-test lipid panel and HbA1c (glycated hemoglobin, a 3-month average glucose marker) at 8–12 weeks when used cardiometabolically: Quantify the personal response and allow rational decisions about continued use, dose adjustment, or co-administered statin/antidiabetic dose changes; this also catches the small minority of users in whom mastic produces no measurable benefit.
Separate mastic from proton-pump inhibitors when targeting H. pylori: If mastic is used for the H. pylori indication, take it at least 2–3 hours apart from any concomitant PPI to avoid the apparent negative interaction observed in the Dabos 2010 trial.
Discontinue and seek medical evaluation for systemic allergic symptoms: Any sign of urticaria, angioedema (sudden swelling beneath the skin or mucous membranes that can compromise breathing), wheezing, or systemic allergic reaction warrants immediate discontinuation and medical assessment.
Use only food-grade Chios PDO (Protected Designation of Origin) product or third-party-tested supplements: This mitigates risks of adulteration with non-PDO resins of unknown chemistry and contaminants; sourcing is discussed further in the Sourcing and Quality section.

Therapeutic Protocol

A standard protocol for mastic gum varies by indication. The most common approaches used by integrative gastroenterology and metabolic medicine practitioners are:

Functional dyspepsia: 350 mg three times daily for at least 3 weeks, taken before or with meals. This is the protocol used in the Dabos 2010 trial and is the basis for the European Medicines Agency traditional-use indication.
Cardiometabolic / dyslipidemia (crude mastic): 1 g/day in divided doses for at least 8 weeks, then re-test lipids. This is the CHIOS-MASTIHA dosing.
Cardiometabolic (essential oil preparation): 200 mg/day of Chios Mastiha Essential Oil capsules for 8–12 weeks, per the MASTIHA-OIL and Gioxari trials. This is a different preparation from crude resin and has different dose-equivalence; the two should not be substituted milligram-for-milligram.
Inflammatory bowel disease (adjunctive): 2.2–2.8 g/day in divided doses for 1–6 months adjunctive to standard medical therapy, as used in Greek IBD trials.
Helicobacter pylori (adjunctive only): 1 g three times daily for 14 days alongside standard antibiotic regimen; mastic monotherapy is not adequate for eradication. Separate by several hours from any concomitant PPI.
Oral health: chewing 1 g of resin for 10–15 minutes daily, or use of a mastic-based toothpaste twice daily, for at least 4 weeks before assessing effect on plaque and breath.

Where competing approaches exist, the main alternative to oral mastic in functional dyspepsia is conventional acid-suppression (PPIs, H2 blockers); to mastic in H. pylori it is standard antibiotic triple or quadruple therapy; to mastic for dyslipidemia it is dietary modification, plant sterols, fiber, berberine, or statins. None of these is framed as the default — choice depends on goals, tolerance, and prior response.

The Mastiha Research Center on Chios and the Chios Mastic Gum Growers Association have funded or co-led most modern clinical trials; the Harokopio University group in Athens (Kaliora, Amerikanou) and the cardiology group at the General Hospital of Chios (Kartalis, Afendoulis) have published the largest body of clinical work and effectively define current practice.

Best time of day: For dyspepsia, dose 15–30 minutes before meals. For cardiometabolic indications, with breakfast and dinner. The act of chewing the resin in the morning may produce the most marked salivary and oral-microbiome effect.
Half-life and dosing frequency: Mastic is a multi-component natural product without a single defined plasma half-life. Triterpene acids and monoterpenes have markedly different pharmacokinetics. The empirical clinical practice of split twice- to thrice-daily dosing reflects this rather than data on a defined half-life.
Single vs. split doses: Split dosing is the empirical standard across all major trials and is preferable to a single bolus, both for tolerability and for sustained effect.
Genetic polymorphisms: No mastic-specific pharmacogenetic data exist. Genotype-related modifiers of lipid (APOE), glucose (TCF7L2, a gene strongly associated with type 2 diabetes risk and insulin secretion), or inflammatory response (variants in NF-κB pathway components) may plausibly influence response but have not been characterized in trials.
Sex-based differences: No sex-stratified protocol differences are warranted by current data.
Age-related considerations: Older adults often have established polypharmacy and dental work; lower-dose initiation (250–500 mg/day) and capsule rather than chewing form is reasonable.
Baseline biomarker influence: Individuals with elevated baseline total cholesterol (>200 mg/dL), elevated fasting glucose, elevated alanine aminotransferase, or symptomatic dyspepsia are more likely to show measurable benefit; near-optimal baseline values warrant lower a priori expectation.
Pre-existing health conditions: Active IBD users should treat mastic strictly as adjunctive to gastroenterology-led care; H. pylori users should not abandon standard antibiotic eradication for mastic monotherapy.

Discontinuation & Cycling

Lifelong vs. short-term use: Mastic is generally used in defined courses (3 weeks for dyspepsia, 8–12 weeks for cardiometabolic indications, 1–6 months for IBD adjuncts) rather than indefinitely. There is no clinical-trial evidence supporting or refuting indefinite long-term daily use, and trial data extend at most to ~6 months.
Withdrawal effects: No withdrawal syndrome has been described. Symptomatic benefits in dyspepsia or IBD may regress after stopping if the underlying disease activity remains, but this is recurrence, not withdrawal.
Tapering: No taper is required; mastic can be stopped abruptly without rebound.
Cycling: Cycling is not formally studied. A pragmatic pattern used by some integrative practitioners is 3 months on / 1 month off to reassess symptomatic and biomarker effect, though this rests on convention rather than data. For oral and dyspepsia indications, intermittent use as needed is reasonable.
Re-testing biomarkers after a course: For cardiometabolic users, repeat the lipid panel and fasting glucose 8–12 weeks after starting and again 4–6 weeks after stopping to characterize the response and persistence of effect.

Sourcing and Quality

Look for Chios Protected Designation of Origin (PDO) certification: Authentic Chios mastiha has held EU PDO status since 1997 and is regulated by the Chios Mastic Gum Growers Association. PDO product is the only variety with the established phytochemical profile underpinning the clinical trials. Non-Chios resins from other Pistacia species or other geographies have different chemistry and unknown clinical equivalence.
Choose third-party-tested capsules for supplemental use: Reputable supplement brands often source PDO-certified Chios mastiha and submit to third-party identity, purity, and contaminant testing. Look for certificates of analysis specifying species (Pistacia lentiscus var. chia), origin, and absence of heavy-metal and microbial contamination.
Distinguish crude resin, polymer-free mastic, and essential oil: The CHIOS-MASTIHA trial showed that crude mastic produced significant cholesterol and glucose effects while polymer-free mastic and powder mastic did not at the same total dose, suggesting that the polymer fraction may contribute to bioactivity and that not all mastic preparations are interchangeable. Chios Mastiha Essential Oil (CMO) is a separate preparation studied at 200 mg/day; do not substitute essential-oil dosing for crude-resin dosing.
Reputable suppliers: The Chios Mastic Gum Growers Association sells through licensed distributors such as Mastihashop. Larger supplement brands offering mastic gum capsules at the time of writing include Jarrow Formulas, Source Naturals, NOW Foods, and Life Extension. Brand availability and quality change over time and verification of current third-party testing is preferable to brand-name reliance.
Avoid products without species and origin specified: Generic “mastic” or “mastic gum” labelling without species (Pistacia lentiscus var. chia) and Chios origin should be treated with caution, as related Pistacia species (P. atlantica, P. khinjuk) have different phytochemistry and are sometimes substituted.

Practical Considerations

Time to effect: Dyspepsia symptom relief is typically apparent within 1–3 weeks. Cholesterol and glucose changes require 8 weeks of consistent use to be measurable. Inflammatory bowel disease symptom improvements emerge over 1–3 months. Oral health changes (plaque indices, halitosis) appear over 4 weeks of regular use.
Common pitfalls: (a) Treating mastic as a primary H. pylori eradication agent rather than as an adjunct, leading to under-treated infection. (b) Substituting essential-oil dosing for crude-resin dosing or vice versa. (c) Using non-Chios or generic Pistacia resin and assuming clinical-trial equivalence. (d) Overusing the chewing form to the point of jaw fatigue or dental damage, particularly in those with old amalgam fillings. (e) Discontinuing too early (before 8–12 weeks) and concluding “no effect” for cardiometabolic indications.
Regulatory status: In the European Union, mastic is approved as a Traditional Herbal Medicinal Product for mild dyspeptic disorders and minor skin inflammation under Directive 2004/24/EC. In the United States, mastic gum is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) without disease-treatment claims. It is not a prescription drug in any major market.
Cost and accessibility: Capsule-form mastic gum supplements are widely available online and in larger natural-products retailers; typical monthly costs at common dosing range from approximately $20 to $50. PDO-certified raw resin is more expensive on a per-gram basis but available through specialty importers. Mastic is not difficult to access and is not exceptionally expensive relative to other targeted supplements.

Interaction with Foundational Habits

Sleep: No direct sleep effects are documented. Indirect benefit is plausible in patients whose dyspepsia or reflux symptoms disturb sleep — improved nighttime epigastric symptoms can secondarily improve sleep quality. There is no stimulant or sedative pharmacology and no known timing constraint relative to sleep onset.
Nutrition: Direct positive interaction with a Mediterranean dietary pattern is biologically coherent — mastic is itself a Mediterranean botanical, and the cholesterol-lowering signal in trials was observed against a background of typical Greek diet. Mastic does not appear to deplete specific nutrients. For cardiometabolic indications, combining mastic with established dietary measures (soluble fiber, plant sterols, oily fish) is reasonable and likely additive in direction.
Exercise: No documented direct interaction with exercise or training adaptation; mastic is not known to blunt or potentiate hypertrophy, mitochondrial biogenesis, or aerobic adaptation. Animal work on glycemic control suggests greater benefit when mastic is combined with regular exercise, but human exercise-by-mastic interaction trials do not exist.
Stress management: No formal cortisol or hypothalamic-pituitary-adrenal axis data exist for mastic. The act of chewing in general has modest acute stress-modulating effects via masseter activation and parasympathetic engagement; whether mastic chewing produces a meaningful additional effect is not characterized. Direction: probably indirect/none; mechanism uncertain; no specific timing considerations.

Monitoring Protocol & Defining Success

Before starting mastic gum supplementation, a baseline assessment provides a reference for tracking change. The relevant labs depend on the indication and the user’s broader cardiometabolic status.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Total cholesterol	150–200 mg/dL	Primary cardiometabolic outcome in mastic trials	Conventional reference: <200 mg/dL desirable. Fasting required (12 h).
LDL-C	<100 mg/dL (lower in high cardiovascular risk)	Direct target of mastic’s hypolipidemic effect	Low-density lipoprotein cholesterol; calculated from standard lipid panel; fasting preferred.
HDL-C	>60 mg/dL	Pattern of change with mastic varies; useful to track	High-density lipoprotein cholesterol; higher values protective; mastic essential oil shows small increases.
Triglycerides	<100 mg/dL (functional); <150 mg/dL (conventional)	Mastiha essential oil reduces by ~15% in trials	Strict 12-h fast required.
Fasting plasma glucose	70–90 mg/dL (functional); <100 mg/dL (conventional)	Small but reproducible mastic-induced reductions	Morning fasting sample.
HbA1c	<5.3% (functional); <5.7% (conventional non-diabetic)	Captures medium-term glucose response over 3 months	Glycated hemoglobin; no fasting required; reflects ~3-month glycemic average.
Alanine aminotransferase	<19 U/L women, <30 U/L men (functional); <40 U/L (conventional)	Reduced in mastic essential oil trial; tracks liver-fat trajectory	Often abbreviated ALT; fasting preferred; affected by recent strenuous exercise.
C-reactive protein, high-sensitivity	<1 mg/L	Tracks systemic inflammation; relevant for IBD adjunct use	Often abbreviated hs-CRP; avoid measuring during acute infection.
Adiponectin	Higher is better (sex- and assay-specific reference)	Increased with Chios Mastiha Essential Oil in metabolic syndrome trial	Optional; available through some specialty panels.
Fecal calprotectin (in IBD)	<50 µg/g (functional); <120 µg/g (conventional remission cutoff)	Mastic adjunct improved fecal inflammatory markers in IBD trials	Timing relative to flares matters; specific stool collection protocol.
Body weight, waist circumference, body composition	Individualized	Tracked in MASTIHA-OIL and Gioxari trials	Standardized morning measurement; bioimpedance optional.

For ongoing monitoring, lipid panel, fasting glucose, and HbA1c are reasonable to repeat at 8–12 weeks after initiation and then every 6–12 months while supplementation continues. For inflammatory bowel disease use, fecal calprotectin and inflammatory markers should follow standard gastroenterology-led monitoring schedules. For oral-health applications, simple at-home tracking of plaque index by a hygienist at 6-month dental visits and breath-volatile-sulfur monitoring (clinical or consumer-grade meter) are sufficient.

Qualitative markers worth tracking include:

Frequency and severity of upper-abdominal pain, postprandial fullness, and heartburn (Leuven Postprandial Distress Scale or simple symptom diary).
Stool consistency, frequency, and presence of blood (in IBD use).
Subjective oral comfort, perceived breath freshness, and partner/dental-hygienist feedback on plaque.
Energy, sleep quality, and post-meal comfort.
Onset of any new headache, jaw discomfort, dermatitis, or allergic symptoms (warning signs warranting discontinuation).

Emerging Research

Chios Mastic Water in Dyspepsia: NCT06909890 is a 60-participant randomized, double-blind, placebo-controlled 3-month trial in adults with dyspepsia testing a carbonated beverage enriched with 0.2% Chios mastic water (an aqueous by-product of mastic processing). It will test whether a low-dose, palatable delivery format produces clinically meaningful symptom and biomarker change.
Chios Mastic Toothpaste in Orthodontic Patients: NCT06766097 is testing mastic-containing toothpaste vs. placebo in 30 adolescents undergoing fixed orthodontic treatment, with halitosis (volatile sulfur compounds) and plaque indices as primary endpoints. The first published results are reflected in the Alexiou 2025 trial.
Metabolic biomarkers in Hashimoto’s thyroiditis and psoriasis: NCT04693936 is an active, non-recruiting, 200-patient longitudinal study of nutraceutical combinations (including mastiha-based components) in autoimmune disease, exploring whether the immune-modulating signal seen in IBD trials extends to other immune-mediated conditions.
Mastiha as adjunct to bismuth quadruple therapy for H. pylori: Building on the Tulsian et al., 2026 pilot trial, larger randomized confirmatory work is needed to determine whether mastic adjunct meaningfully improves eradication rates and tolerability of standard quadruple therapy. This is one of the most clinically actionable open questions.
Long-term safety and dosing ceiling: Most mastic trials end at 3–6 months. The maximum safe long-term daily dose remains undefined, and longer-duration safety trials (12+ months) are an important gap noted in the Soulaidopoulos et al., 2022 review.
Microbiota-mediated mechanisms: The MAST4HEALTH program (Amerikanou et al., 2021) and Mastiha-microRNA-155 work (Amerikanou et al., 2021) point toward a coherent gut-microbiota and Th17-dependent mechanism that may explain effects across multiple indications. Future research should test whether baseline microbiota composition predicts response.
Cardiometabolic confirmatory trial: A multicenter randomized confirmatory trial of crude mastic vs. placebo in adults with established dyslipidemia, of sufficient size and duration to support a meta-analysis, would substantially strengthen — or weaken — the cardiovascular case. The current evidence base is consistent in direction but limited in size.
Anticancer translational work: Whether the reproducible in vitro and animal anticancer signals translate to humans is an open question. Phase I studies in colorectal cancer survivors or in chemoprevention populations would represent the next reasonable step but have not been undertaken.

Conclusion

Mastic gum is a botanical resin with one of the longest continuously documented medicinal histories in the Mediterranean and an expanding modern clinical evidence base. The most consistent randomized-trial evidence supports its use for symptom relief in functional dyspepsia (the indication formally recognized by the European Medicines Agency), modest reductions in total and “bad” cholesterol over an 8-week course, small reductions in fasting glucose, and adjunctive support in active and quiescent inflammatory bowel disease. Effects on body composition, blood pressure, and oxidative-stress markers have been reported in single trials of the essential-oil preparation. The original Helicobacter pylori finding that drew modern attention to mastic has translated into only modest monotherapy eradication rates; current best evidence positions mastic as a potential adjunct rather than replacement for standard antibiotic regimens.

The intervention has been well tolerated across all major trials, with mild gastrointestinal complaints, occasional contact dermatitis, and chewing-related dental and jaw concerns the principal documented risks. Most published trials have been Greek or Greek-led and supported by mastic-industry research bodies, a structural conflict of interest that should be borne in mind. Within this framing, mastic is a reasonable, well-characterized botanical option to consider for the indications where its evidence base is strongest.

Top - Benefits - Risks - Protocol

Mastic Gum for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Functional Dyspepsia Symptom Relief

Total Cholesterol and LDL Reduction

Inflammatory Bowel Disease Activity

Low 🟩

Anti-Helicobacter pylori Activity

Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement ⚠️ Conflicted

Oral Plaque and Gingival Health

Cardiometabolic Risk in Metabolic Syndrome

Speculative 🟨

Anticancer Activity

Bone Loss Protection

Cognitive and Stress Benefits via Chewing

Benefit-Modifying Factors

Potential Risks & Side Effects

Low 🟥

Gastrointestinal Discomfort

Allergic Contact Dermatitis and Cross-Reactivity

Tooth and Jaw Strain from Heavy Chewing

Mercury Liberation from Amalgam Fillings

Gastrointestinal Bezoar (with Excessive Chewing-Resin Intake)

Speculative 🟨

Drug-Metabolism Interactions

Pregnancy and Lactation Safety

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion